Mar 05, 2026 8:30am EST FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
Mar 02, 2026 8:30am EST FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
Feb 24, 2026 4:30pm EST FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
Feb 10, 2026 8:30am EST FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University
Feb 05, 2026 8:30am EST FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
Jan 06, 2026 8:30am EST FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference